Related Experiment Video
Updated: Feb 10, 2026
Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae
Published on: June 13, 2025
The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
1Department of Biochemistry & Biomedical Sciences and the Michael G. DeGroote Institute for Infectious Diseases Research , McMaster University , 4H18 Health Sciences Centre, 1280 Main Street West , Hamilton , Ontario L8S 4K1 , Canada.
Abstract:
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the World Health Organization as a critical priority for development of new therapeutics due to high levels of intrinsic and acquired antibiotic resistance. Other challenges include its versatility (it can persist in the environment and most strains are capable of causing disease in compromised hosts), robust efflux mechanisms that limit drug penetration, and the propensity to form antimicrobial-tolerant biofilms. Novel therapeutics in development to prevent or treat P. aeruginosa infections include vaccines, biologics such as antimicrobial peptides and therapeutic antibodies, virulence inhibitors, antimicrobials with novel targets, antibody-drug conjugates, resistance inhibitor-antibiotic or antibiotic-potentiator combinations, and bacteriophages or phage-derived lysins.
Insights
Pseudomonas aeruginosa infections are a critical threat due to antibiotic resistance and biofilm formation. New therapeutics, including vaccines, biologics, and novel antimicrobials, are under development to combat this challenging pathogen.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen.
- It is a critical priority for new therapeutic development due to high antibiotic resistance.
- Challenges include its versatility, efflux mechanisms, and biofilm formation.
Purpose of the Study:
- To review novel therapeutic strategies against Pseudomonas aeruginosa infections.
- To highlight the urgent need for new treatments.
Main Methods:
- Literature review of current and emerging therapeutics.
- Analysis of Pseudomonas aeruginosa resistance mechanisms and virulence factors.
Main Results:
- Multiple novel therapeutic approaches are in development.
- These include vaccines, biologics (antimicrobial peptides, antibodies), virulence inhibitors, novel antimicrobials, antibody-drug conjugates, resistance inhibitors, and bacteriophages/lysins.
Conclusions:
- Significant efforts are underway to develop new treatments for Pseudomonas aeruginosa.
- A diverse range of therapeutic strategies are being explored to overcome resistance and pathogenicity.
Related Concept Videos
01:13Therapeutic Index
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:29Microorganisms in Medicine and Therapeutics
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:31Skeletal Muscle Relaxants: Therapeutic Uses